TICKERNERD
Menu
ACETACETHealthcare · Biotechnology

ACET Stock Forecast: Adicet Bio, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$6.25
−3.40% on the day

The 6 Wall Street analysts covering Adicet Bio, Inc. hold a median 12-month price target of $24 — +284.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 5 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$60.8M
Ticker Nerd rank
38 / 100
Median analyst target
$24
Analysts covering
6
Revenue$0.0
Operating income−$22.3M
Net income−$21.4M
Free cash flow−$20.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.5%
1M
−34.8%
YTD
−25.8%
1Y
−60.9%
From 52W high
−62.4%
From 52W low
+2.3%
$6
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACET stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adicet Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
80
Accruals
78
Growth
67
Revisions
51
Issuance
43
Quality
36
Volatility
34
Momentum
21
Value
8

Size (80): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACET stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACET, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26ACETHigh $90Median $24Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $18Median $24High $90

The green dot is the last close — the median target sits +284.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
29 Sept 2026WedbushMaintainsOutperform$25 → $28
28 Sept 2026HC Wainwright & Co.MaintainsBuy$27 → $34
18 Sept 2026HC Wainwright & Co.ReiteratesBuy$27
18 Sept 2026HC Wainwright & Co.ReiteratesBuy—
6 Aug 2026GuggenheimMaintainsBuy$100 → $90
6 Aug 2026GuggenheimMaintainsBuy—
5 May 2026JefferiesAssumesBuy$8.00 → $19
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026GuggenheimMaintainsBuy—
21 Jan 2026HC Wainwright & Co.MaintainsBuy—
6 Jan 2026Canaccord GenuityMaintainsBuy—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
8 Oct 2025GuggenheimMaintainsBuy—
19 Sept 2025GuggenheimReiteratesBuy—
23 July 2025HC Wainwright & Co.AssumesBuy$4.00
21 Mar 2025GuggenheimReiteratesBuy—
7 Mar 2025Citizens Capital MarketsReiteratesMarket Perform—
7 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
6 Feb 2025JMP SecuritiesReiteratesMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACET appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACET vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Adicet Bio, Inc. returned −60.9% against +17.3% for the S&P 500, dividends included.

ACET vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26ACETS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACET analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Adicet Bio, Inc. (ACET) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
0.4×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−78.1%

Higher than 16% of US stocks

Return on assets
−41.7%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Adicet Bio, Inc. (ACET) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adicet Bio, Inc. has a market value of $60.8M and an enterprise value of −$35.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$99.0M.

  • Diluted earnings per share, trailing twelve months: $−11.45.

  • Free cash flow in the twelve months to 30 June 2026: −$85.0M.

  • Shares outstanding: 9.4M.

  • Trailing P/E: −0.4×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Adicet Bio, Inc. employs 102 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

ACET vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACETAdicet Bio, Inc.$60.8M
38
ELOXEloxx Pharmaceuticals, Inc.$62.2M
12
INKTMiNK Therapeutics, Inc.$60.6M
57
GUTSFractyl Health, Inc.$60.5M
30
PLRXPliant Therapeutics, Inc.$63.8M
67
XLOXilio Therapeutics, Inc.$59.9M
73
KLRSKalaris Therapeutics, Inc.$59.3M
16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adicet Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACET news & analysis

Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months

MarketBeat · 3 Oct 2026positive

Adicet Bio reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus (SLE), including those with lupus nephritis. The therapy delivered a 54% lupus remission rate at 12 months.

Why it matters — A watcher of Adicet Bio would care because this clinical data supports the potential of prula-cel as a treatment for SLE and lupus nephritis, a key developmental milestone for the company's pipeline.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 30 Sept 2026neutral

Adicet Bio announced an inducement award granted on September 30, 2026, under Nasdaq Listing Rule 5635(c)(4). A newly hired individual in September 2026 received non-qualified stock options to purchase 725 shares of Adicet's common stock.

Why it matters — Adicet watchers may track this equity inducement grant as a routine retention incentive for a newly hired employee in the company's ongoing operations.

Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript

Seeking Alpha · 28 Sept 2026positive

Adicet Bio, Inc. discussed positive data for its candidate prula-cel in a transcript covering its plans for a pivotal study in lupus nephritis. The discussion focused on the encouraging results and the company's intended next steps toward a pivotal trial.

Why it matters — A shareholder would care because positive prula-cel data and a planned pivotal study represent a potential major advancement in ACET's pipeline for lupus nephritis.

Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Business Wire · 28 Sept 2026positive

Adicet Bio announced positive safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis.

Why it matters — The positive Phase 1 results for prula-cel signal progress in Adicet's allogeneic gamma delta CAR-T cell pipeline for autoimmune diseases.

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Business Wire · 25 Sept 2026neutral

Adicet Bio announced it will host a webcast to present clinical data from the Phase 1 study of prulacabtagene leucel (prula-cel, formerly ADI-001) in patients with systemic lupus erythematosus with or without lupus nephritis.

Why it matters — The upcoming presentation of Phase 1 data on prula-cel is significant for ACET watchers, as it will provide an early look at the investigational therapy's results in an autoimmune disease indication.

FAQ

Frequently asked questions about ACET stock

What is the ACET stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Adicet Bio, Inc. have a median 12-month price target of $24, with estimates ranging from $18 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACET stock a buy right now?

Of the 6 analysts covering Adicet Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adicet Bio, Inc. 38 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACET?

As at 5 Oct 2026, Adicet Bio, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).

Will ACET stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +284.0% from the last close, and Ticker Nerd's factor model ranks Adicet Bio, Inc. 38 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACET stock forecast for 2030?

No analyst covering Adicet Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACET are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $90 over the next 12 months.

How has ACET stock performed over the past year?

Adicet Bio, Inc. returned -60.9% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adicet Bio, Inc. do?

Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

What is the latest news on ACET?

The most recent item we track (MarketBeat, 3 Oct 2026): "Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months". Adicet Bio reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus (SLE), including those with lupus nephritis. The therapy delivered a 54% lupus remission rate at 12 months.

Company

About Adicet Bio, Inc.

Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications. Adicet Bio’s research and development efforts are aimed at advancing differentiated cell therapy candidates that combine immune-cell engineering with tumor-targeting or disease-modifying mechanisms. The company operates within the biotechnology and health technology sectors, where its programs contribute to the broader development of next-generation immunotherapies for patients with serious and difficult-to-treat conditions. Adicet Bio is headquartered in Boston, Massachusetts.

CEO Mr. Chen Schor BA, CPA, M.B.A. · 102 employees · United States · https://www.adicetbio.com